- Home
- RBLX vs BIIB Comparison
RBLX vs BIIB Comparison
Compare RBLX & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBLX
- BIIB
- Stock Information
- Founded
- RBLX 2006
- BIIB 1978
- Country
- RBLX United States
- BIIB United States
- Employees
- RBLX N/A
- BIIB N/A
- Industry
- RBLX EDP Services
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- RBLX Technology
- BIIB Health Care
- Exchange
- RBLX Nasdaq
- BIIB Nasdaq
- Market Cap
- RBLX 26.0B
- BIIB 25.1B
- IPO Year
- RBLX 2021
- BIIB 1991
- Fundamental
- Price
- RBLX $52.18
- BIIB $164.23
- Analyst Decision
- RBLX Buy
- BIIB Buy
- Analyst Count
- RBLX 22
- BIIB 25
- Target Price
- RBLX $54.38
- BIIB $258.57
- AVG Volume (30 Days)
- RBLX 9.6M
- BIIB 1.7M
- Earning Date
- RBLX 10-31-2024
- BIIB 10-30-2024
- Dividend Yield
- RBLX N/A
- BIIB N/A
- EPS Growth
- RBLX N/A
- BIIB 10.05
- EPS
- RBLX N/A
- BIIB 11.06
- Revenue
- RBLX $3,363,735,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- RBLX $59.15
- BIIB N/A
- Revenue Next Year
- RBLX $20.45
- BIIB N/A
- P/E Ratio
- RBLX N/A
- BIIB $14.85
- Revenue Growth
- RBLX 27.98
- BIIB N/A
- 52 Week Low
- RBLX $29.55
- BIIB $153.62
- 52 Week High
- RBLX $55.10
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- RBLX 61.64
- BIIB 42.84
- Support Level
- RBLX $48.61
- BIIB $158.44
- Resistance Level
- RBLX $53.16
- BIIB $160.63
- Average True Range (ATR)
- RBLX 1.72
- BIIB 4.14
- MACD
- RBLX -0.41
- BIIB 0.94
- Stochastic Oscillator
- RBLX 59.18
- BIIB 47.71
About RBLX Roblox Corporation
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or "experiences") for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.